Sanofi (NASDAQ: SNY)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Sanofi Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sanofi Company Info
A global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.
News & Analysis
This vaccine candidate could be approved in newborns and infants later this year.
It's difficult to imagine a future where healthcare isn't in high demand.
This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease.
Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union.
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.
Is now the time to buy Sanofi and Intel?
The number changes quickly.
Sanofi and Regeneron's Dupixent could be months away from regulatory approval for another skin condition in the U.S.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 02/07/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Podcast Episodes
Earnings Transcripts
SNY earnings call for the period ending December 31, 2022.
SNY earnings call for the period ending September 30, 2022.
SNY earnings call for the period ending June 30, 2022.
SNY earnings call for the period ending March 31, 2022.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.